Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Mylan’s EpiPen Price Hike Draws Criticism

By Stephanie Guzowski | August 22, 2016

The pharmaceutical company Mylan holds a virtual monopoly on epinephrine injections. In 2007, the company acquired the EpiPen, an auto-injector that precisely calibrates the dosage of epinephrine, used to treat severe allergic reactions in an emergency situation.

But a two-pack of EpiPens cost about $57 when Mylan acquired the devices. Since then, the price of a pack of EpiPens increased to approximately $500 from around $100 in 2008, a hike of nearly 450 percent, reported NBC News.

After Sanofi voluntarily recalled its auto-injector, Auvi-Q, last year over dosage miscalibrations, Mylan gained full control of the market.

“They did a pretty good job marketing themselves where it’s just like Kleenex,” John Vann, MD, a pediatrician in Omaha, Nebraska, said in the NBC article. “People don’t say ‘epinephrine auto-injector,’ they say ‘EpiPen.’”

In a statement emailed to NBC, Mylan said its prices have “changed over time to better reflect important product features and the value the product provides. We’ve made a significant investment to support the device over the past years.”

Mylan noted that commercially insured patients have used its $100 savings program, with nearly 80 percent getting their EpiPens for no cost. MarketWatch reported that the savings program “enables a free or low co-pay for those with good insurance plans, but barely makes a dent for those with increasingly common high-deductible plans or no insurance.”

The news of the EpiPen’s significant price-hike history was met with criticism alike from doctors and patients, who said they’re outraged at the costly difficulty in obtaining the lifesaving auto-injectors. Some patients are even turning to manual syringes as a cheaper alternative, which can be unsafe because it’s more complicated to administer the correct dosage.

Photo credit: J. David Ake/AP

Investor Mark Cuban tweeted, “…life-saving drugs should be capped and locked to get U.S. approval.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE